What Is Thymosin Alpha-1?
Thymosin alpha-1, usually shortened to:
Tα1
is a naturally occurring 28-amino-acid peptide associated with the thymus and immune system.
Its pharmaceutical synthetic form is called:
thymalfasin.
You may also see the brand name:
Zadaxin.
FDA specifically notes that thymalfasin is the chemically synthesized form of thymosin alpha-1, while Zadaxin is a finished drug product marketed in other countries.
Tα1 became interesting to researchers because the thymus plays a major role in:
T-cell development + immune maturation + immune surveillance + coordination of adaptive immunity.
Unlike something marketed simply as an “immune booster,” thymosin alpha-1 is better described as:
an immunomodulatory peptide.
That distinction matters.
What Does “Immunomodulatory” Mean?
An immunomodulator changes or regulates immune activity.
That is not always the same thing as simply:
“boosting immunity.”
The immune system has to balance two problems:
too little activity → poor response to pathogens
and:
too much or poorly controlled activity → damaging inflammation or autoimmunity.
Tα1 research suggests effects involving both:
immune activation + immune regulation.
That makes the biology considerably more nuanced than:
“take this and your immune system gets stronger.”
How Might Thymosin Alpha-1 Work?
Research suggests Tα1 influences both innate and adaptive immunity.
Proposed effects include changes involving:
- T-cell maturation
- T-cell activity
- Dendritic cells
- Natural killer cells
- Toll-like receptor signaling
- Cytokines
- Antigen presentation
- Immune-cell differentiation
- Immune recovery after suppression
Reviews describe Tα1 as influencing T-cell function and broader immune regulation rather than acting through one single receptor pathway.
In simplified terms:
Thymosin alpha-1 may help immune cells communicate, mature, and respond appropriately.
But the exact effect depends heavily on:
disease + immune state + timing + other treatments.
What About T Cells?
This is one of the strongest themes in the Tα1 literature.
T cells coordinate many aspects of adaptive immunity.
They include:
CD4 helper T cells
and:
CD8 cytotoxic T cells.
Older sepsis research found Tα1 could increase CD4 counts or improve CD4/CD8-related immune measures in some patients.
It has also been studied for restoring immune function during illnesses associated with:
lymphocyte depletion + immune exhaustion + immune suppression.
So T-cell biology is not marketing fluff here.
It is central to the peptide’s research history.
What About the Thymus?
The thymus is particularly important during childhood and adolescence because immature T cells develop and undergo selection there.
Thymic function declines with age through a process called:
thymic involution.
That partly explains why thymic peptides became interesting in:
immune aging + infection susceptibility + cancer immune surveillance + vaccine response.
But Tα1 does not literally:
regrow the thymus
or reverse age-related thymic involution.
Those claims would go beyond the evidence.
Does Thymosin Alpha-1 “Boost Immunity”?
This phrase is too simplistic.
It may enhance certain immune functions under some conditions.
But research also suggests it can help regulate excessive inflammatory activation.
For example, reviews discuss both:
restoring impaired T-cell responses
and:
modulating overly inflammatory responses.
So a better description is:
immune regulation rather than indiscriminate immune stimulation.
That becomes especially important when discussing:
autoimmune disease + severe infection + cancer immunotherapy.
What About Infections?
Tα1 has been studied extensively in infectious disease.
Research areas include:
- Hepatitis B
- Hepatitis C
- Sepsis
- Severe respiratory infections
- COVID-19
- Tuberculosis
- Opportunistic infections
The strength of evidence varies dramatically depending on the condition.
It should not be described as:
a broad-spectrum antiviral or antimicrobial treatment.
It does not directly kill pathogens the way an antibiotic does.
Its role is more related to:
modifying the host immune response.
What About Hepatitis B?
This is one of the oldest clinical research areas.
Thymalfasin was studied extensively for chronic hepatitis B.
An early review summarized multiple human trials and reported evidence of hepatitis B viral-DNA clearance in some participants, although study sizes were small and findings were not uniformly convincing.
FDA has granted thymalfasin orphan-drug designation for chronic active hepatitis B.
But this is crucial:
orphan designation is NOT FDA approval.
FDA’s own database explicitly lists thymalfasin as:
“Not FDA Approved for Orphan Indication.”
So:
hepatitis B human research → yes
FDA-approved hepatitis B treatment → no.
What About Hepatitis C?
Tα1 was also studied historically in hepatitis C, often in combination with interferon-based therapy.
Some older research suggested possible additional antiviral or immune benefits.
But hepatitis C treatment has changed enormously.
Modern direct-acting antivirals now cure the overwhelming majority of cases.
So much of the old Tα1 hepatitis-C literature has limited relevance to current standard care.
What About Sepsis?
This is one of the most substantial modern Tα1 research areas.
Sepsis creates a strange immune problem.
Early in the illness there may be:
extreme inflammatory activation.
Later, many patients develop:
immune paralysis or immunosuppression.
That can include:
- Low lymphocyte activity
- Reduced antigen presentation
- Secondary infections
- Poor immune responsiveness
That made Tα1 a logical candidate for sepsis research.
Did Early Sepsis Studies Look Promising?
Yes.
A multicenter randomized trial involving 361 patients with severe sepsis found 28-day mortality of:
26.0% with Tα1
versus:
35.0% with control.
However, the primary statistical analysis was borderline and the confidence interval crossed 1.0.
Researchers also observed improvements in the immune marker:
monocyte HLA-DR.
Earlier meta-analyses also suggested possible mortality benefit.
That created substantial optimism.
What Did the Big Modern Sepsis Trial Show?
This changed the picture considerably.
The TESTS Phase 3 trial, published in the BMJ in 2025, was:
- Multicenter
- Double blind
- Randomized
- Placebo controlled
- Conducted across 22 centers
- Included 1,106 adults with sepsis
This was much stronger evidence than the earlier small studies.
The trial did not demonstrate a clear overall mortality benefit sufficient to establish Tα1 as routine sepsis treatment.
That is important because older summaries frequently stop at the promising earlier trials.
What Does the New Sepsis Meta-Analysis Say?
A 2025 systematic review and meta-analysis included:
11 randomized trials
with:
1,927 patients.
When all studies were pooled, Tα1 was associated with lower 28-day mortality:
OR 0.73.
But when researchers restricted the analysis to:
higher-quality studies
or:
multicenter trials,
the mortality benefit was no longer statistically significant.
The authors also concluded that the total sample size remained inadequate for definitive conclusions.
This gives us a much better 2026 description:
Tα1 may help certain immune-defined sepsis subgroups, but it has not been proven to broadly reduce mortality in all sepsis patients.
That’s far more accurate than:
“Tα1 saves people from sepsis.”
What About COVID-19?
Tα1 received a great deal of attention during the COVID-19 pandemic.
Severe COVID can involve both:
hyperinflammation + profound lymphocyte dysfunction.
That made an immune-regulatory peptide scientifically interesting.
A 2023 meta-analysis involving eight studies found an association with lower mortality, but there was high heterogeneity between studies and no significant reduction in mechanical ventilation or hospital stay.
Another systematic review concluded the overall evidence remained uncertain.
So:
COVID research exists.
But:
Tα1 never became an established FDA-approved COVID treatment.
What About Severe Acute Pancreatitis?
This is a newer area.
A 2025 systematic review and meta-analysis examined five randomized trials involving 706 patients with severe acute pancreatitis.
The research focused on whether Tα1 could improve immune regulation, reduce inflammation, and reduce infections.
This remains an investigational area.
It doesn’t mean Tα1 is approved for pancreatitis.
What About Cancer?
Tα1 has a long research history in oncology.
This makes sense because effective antitumor immunity depends heavily on:
T cells + antigen presentation + dendritic cells + immune surveillance.
Researchers have studied Tα1 alongside:
- Chemotherapy
- Radiotherapy
- Interferon
- Cancer immunotherapy
- Immune checkpoint inhibitors
Cancer types investigated include:
- Non-small-cell lung cancer
- Hepatocellular carcinoma
- Melanoma
- Other solid tumors
A 2026 review concluded that preclinical and clinical evidence suggests possible benefit as an adjunctive immunomodulator, but the human evidence remains limited and heterogeneous.
So this is promising science.
It is not proof that Tα1 treats cancer.
Does Tα1 Kill Cancer Cells?
That is too simplistic.
Its major clinical interest is probably:
helping regulate the immune environment around cancer.
Potential mechanisms include:
- Improved T-cell activity
- Better antigen presentation
- Changes in tumor-associated macrophages
- Improved immune infiltration
- Modulation of the tumor microenvironment
A 2026 review specifically discusses Tα1 as a potential partner with immune checkpoint inhibitors.
But:
immune modulation ≠ chemotherapy.
And:
preclinical antitumor activity ≠ proven cancer cure.
What About “Cold” Tumors?
Tumors sometimes get described as:
“hot”
or:
“cold.”
A hot tumor has relatively strong immune-cell infiltration.
A cold tumor has little effective immune activity inside the tumor environment.
Current Tα1 research is exploring whether it can help shift immune signaling and increase immune infiltration in some tumors.
That’s exciting.
But it remains translational research rather than an established universal treatment strategy.
Does Tα1 Make Immunotherapy Work Better?
Potentially—but we don’t know enough yet.
Recent reviews describe preliminary evidence that Tα1 could complement:
immune checkpoint inhibitors.
Possible benefits include:
- Greater antitumor immune activity
- Changes in tumor immune infiltration
- Potential reduction in some immune-related adverse events
But researchers explicitly say larger and longer clinical studies are needed.
So:
possible adjunct → yes
proven immunotherapy enhancer → no.
What About Chemotherapy?
Chemotherapy can suppress:
- Bone marrow
- Lymphocytes
- T-cell function
- General immune capacity
Tα1 has therefore been studied as an adjunct during cancer treatment.
Some clinical literature reports improvements in immune markers or reductions in treatment-related immune suppression.
But it is not an established replacement for:
chemotherapy + radiotherapy + immunotherapy + surgery.
Its research role is adjunctive.
What About Vaccine Response?
This is another legitimate Tα1 research area.
People with weakened immune systems may mount weaker vaccine responses.
Tα1 has historically been studied as an:
vaccine-response enhancer
in immunocompromised or older populations.
That doesn’t mean everyone should use Tα1 before vaccination.
Its clinical benefit depends on population and vaccine context.
What About Older Adults?
Aging is associated with:
thymic involution + reduced naïve T-cell output + immune senescence.
That makes thymic peptides interesting for:
immunosenescence research.
But there is no convincing evidence demonstrating that Tα1:
- Reverses immune aging
- Rejuvenates the thymus
- Extends lifespan
- Prevents all infections in older adults
So:
healthy immune aging → valid research area
while:
immune rejuvenation → not established.
Is Tα1 a Longevity Peptide?
Not in any proven sense.
Its immune biology makes it relevant to aging research.
But we do not have evidence showing Tα1:
extends human lifespan.
Calling it a “longevity peptide” is mostly a wellness-market classification rather than a demonstrated outcome.
What About Autoimmune Disease?
This is where the phrase:
“immune booster”
becomes especially problematic.
Autoimmune disease is characterized by immune activity targeting the body’s own tissues.
If Tα1 simply “turned immunity up,” that could theoretically be undesirable.
But Tα1 appears to have more complex immune-regulatory effects.
Reviews discuss potential effects involving:
T-regulatory cells + cytokines + innate immunity + adaptive immunity.
That has generated research interest in autoimmune conditions.
However:
Tα1 is not an established treatment for autoimmune disease.
And it should not be presented as universally safe merely because it is described as “natural” or “immune balancing.”
What About Chronic Infections?
Tα1 is commonly marketed for:
- Lyme disease
- EBV
- CMV
- Chronic viral infections
- Recurrent infections
- Long COVID
Some of these have plausible immune connections.
But there isn’t strong clinical evidence showing Tα1 reliably eliminates:
persistent EBV + Lyme disease + chronic viral reservoirs.
Those should remain discovery/research terms rather than benefit claims.
What About Epstein-Barr Virus?
EBV is heavily controlled by T-cell immunity.
That gives a biological rationale for research into immune-modulating therapies.
But there is no strong evidence establishing Tα1 as:
a treatment for chronic EBV symptoms.
It also should not be marketed as something that “kills EBV.”
What About Lyme Disease?
Same caution.
Lyme disease is caused by:
Borrelia bacteria.
Standard therapy relies on appropriate antibiotic treatment.
Tα1 may be discussed in integrative or immune-support settings, but there is not convincing clinical evidence establishing it as a Lyme treatment.
What About Long COVID?
Long COVID involves several possible mechanisms including:
- Immune dysregulation
- Viral persistence hypotheses
- Autonomic dysfunction
- Metabolic changes
- Microvascular effects
- Inflammation
Tα1 is therefore scientifically interesting.
But as of 2026:
it is not an established Long COVID therapy.
What About Frequent Illness?
People often search Tα1 because they feel like they:
“catch everything.”
But recurrent infections can arise from many different causes:
- Childcare/school exposure
- Poor sleep
- Nutritional deficiencies
- Immunodeficiency
- Certain medications
- Diabetes
- Chronic stress
- Structural sinus/lung problems
Tα1 should not be presented as a universal fix for frequent infections.
What About Wound Healing?
Immune activity is critical to wound healing.
Tα1 has therefore appeared in research involving:
tissue repair + infection prevention + immune regulation.
But this is not one of its strongest clinical indications.
If someone is specifically researching wound repair, peptides such as:
GHK-Cu + thymosin beta-4
have a more direct tissue-repair research history.
Thymosin Alpha-1 vs. Thymosin Beta-4
These are completely different peptides despite both having “thymosin” in their names.
Thymosin Alpha-1
28 amino acids.
Primary research identity:
immune regulation + T-cell biology.
Thymosin Beta-4
43 amino acids.
Primary research identity:
actin + cell migration + wound healing + tissue repair.
And remember:
TB-500
is not simply another name for full-length thymosin beta-4.
So:
Tα1 ≠ Tβ4 ≠ TB-500.
They should never be lumped into one “thymosin peptide” category.
Thymosin Alpha-1 vs. KPV
Tα1
has broad systemic immune-regulatory research involving:
T cells + dendritic cells + severe infection + oncology.
KPV
has a much stronger preclinical identity around:
inflammatory signaling + intestinal inflammation + epithelial biology.
Both can appear in “immune peptides” discussions.
Their evidence and mechanisms are very different.
Thymosin Alpha-1 vs. LL-37
LL-37
is a human antimicrobial peptide that can directly interact with microbes and also strongly influence innate immunity.
Tα1
is primarily an:
immune-regulatory thymic peptide.
LL-37 can have direct antimicrobial effects in laboratory models.
Tα1 generally works more through:
host immune modulation.
And unlike the simplistic phrase “immune peptides,” both can potentially influence inflammation in complicated, context-dependent ways.
Evidence Snapshot
Defined Peptide: Yes
Length: 28 amino acids
Naturally Occurring Human Biology: Yes
Synthetic Drug Form: Thymalfasin
Laboratory Research: Extensive
Animal Research: Extensive
Human Clinical Research: Extensive relative to many peptides
Immune-Modulation Evidence: Strong biological evidence
T-Cell Research: Strong
Hepatitis Research: Yes
Sepsis Research: Extensive, but modern Phase 3 results mixed/negative overall
COVID-19 Research: Yes, inconsistent
Cancer Adjunct Research: Yes, promising but heterogeneous
Vaccine-Response Research: Yes
Human Longevity Evidence: No
FDA Approved in United States: No
Approved/Marketed in Other Countries: Yes
Overall Evidence: A legitimately studied immunomodulatory peptide with a much larger clinical literature than most research peptides, but effectiveness varies substantially by disease and several promising early findings have not held up cleanly in larger modern trials.
What Do We Know?
We know Tα1 has real effects on:
immune biology and T-cell function.
We know its pharmaceutical form:
thymalfasin
has been used and marketed internationally.
We know there is substantial human clinical research involving:
hepatitis + severe infections + sepsis + cancer + vaccine response.
And we know some studies show meaningful immune and clinical signals.
This isn’t a peptide whose reputation rests on:
one rat paper.
What Don’t We Know?
We don’t have strong evidence proving Tα1:
- Prevents ordinary colds
- Prevents every viral infection
- Treats chronic EBV
- Treats Lyme disease
- Treats Long COVID
- Cures hepatitis
- Prevents sepsis
- Reliably reduces mortality in all sepsis patients
- Treats cancer by itself
- Makes chemotherapy work better in every cancer
- Makes immunotherapy universally more effective
- Prevents vaccine failure
- Reverses immune aging
- Rejuvenates the thymus
- Treats autoimmune disease broadly
- Eliminates chronic inflammation
- Extends human lifespan
- Works as a general-purpose “immune booster”
The evidence is much more condition-specific than online descriptions suggest.
What About Safety?
Tα1 has more human exposure information than many research peptides.
A 2024 review surveying human clinical trials described it as generally well tolerated across studied populations.
But that doesn’t mean:
“zero risk.”
The peptide directly modifies immune biology.
Different populations may respond differently.
And FDA has raised separate concerns about compounded Tα1, including:
- Immunogenicity
- Peptide-related impurities
- API characterization
- Insufficient safety data for certain proposed routes of administration
FDA states that available safety-related information is inadequate to fully understand the risks posed by compounded thymosin alpha-1.
That is a product/route/regulatory concern in addition to the biological safety question.
Is Zadaxin FDA Approved?
No — not in the United States.
This is frequently misstated online.
At an FDA advisory committee meeting, FDA explicitly clarified:
products containing thymosin alpha-1 are not FDA approved in the United States.
FDA noted that Zadaxin is approved in other countries.
That gives us the clean distinction:
International pharmaceutical use → yes.
U.S. FDA approval → no.
What About Orphan Drug Status?
Thymalfasin has received multiple FDA:
orphan drug designations.
Examples include proposed use for:
- Chronic active hepatitis B
- DiGeorge anomaly
- Hepatocellular carcinoma
- Malignant melanoma
But FDA explicitly lists those as:
not FDA approved for the orphan indication.
Orphan designation means FDA recognizes development for a rare disease and may provide development incentives.
It is not approval.
This distinction is especially important because websites sometimes point to an FDA orphan designation as proof that a drug is “FDA approved.”
It isn’t.
What About Compounding?
Tα1 currently sits in a complicated U.S. regulatory position.
FDA states that compounded drugs containing Tα1 may present significant risks involving:
immunogenicity + peptide impurities + API characterization
and says available safety information is inadequate to fully assess risk.
FDA also explains that compounded medications are not themselves FDA approved and are not reviewed before marketing for the same:
safety + effectiveness + quality
standards as approved drugs.
So:
published thymalfasin research does not automatically validate every compounded or research-market Tα1 vial.
Research & Regulatory Status
As of September 2026:
Thymosin alpha-1 / thymalfasin is NOT FDA approved in the United States.
FDA has explicitly confirmed that point.
Its drug form, Zadaxin, has been marketed in other countries for various immune-related indications.
It has several U.S. orphan-drug designations, but none of those designations constitutes approval.
FDA also currently identifies compounded Tα1 among substances raising potential safety concerns.
So its status is best described as:
internationally used immunomodulatory drug with substantial clinical research, but unapproved in the United States.
Your Pep Resource Takeaway
Thymosin alpha-1 is probably one of the easiest peptides to misunderstand.
Calling it:
“an immune booster”
makes the science sound much simpler than it is.
The real story is:
thymic peptide → T-cell biology → immune regulation → decades of human research involving hepatitis, serious infection, sepsis, vaccination and cancer.
There is plenty of legitimate science here.
But it also gives us a perfect example of why bigger modern trials matter.
Earlier sepsis studies looked encouraging.
Then a 1,106-person, multicenter, double-blind Phase 3 trial provided a much tougher test of the hypothesis.
A 2025 meta-analysis subsequently found that while pooled studies suggested reduced mortality, the apparent benefit disappeared when researchers focused on higher-quality and multicenter trials.
That’s science doing what it’s supposed to do:
promising signal → larger testing → more nuanced answer.
Tα1 also has genuinely interesting cancer-immunology research, including possible interactions with immune checkpoint therapy, but even a 2026 review describes the clinical evidence as limited and heterogeneous.
So the fairest description is:
Thymosin alpha-1 is a well-studied immunomodulatory peptide with real human clinical evidence and international pharmaceutical use—but its benefits are highly condition-dependent, and the evidence does not support treating it as a universal immune enhancer.
Research Areas / Search Keywords
Thymosin alpha-1, thymosin alpha 1, thymosin α1, Tα1, TA1, thymalfasin, Zadaxin, thymic peptide, thymus peptide, immune peptide, immunomodulatory peptide, immune modulation, immune regulation, immune system, immune health, immune support research, immune boosting research, immunity, weakened immune system, low immunity, frequent infections, getting sick often, recurrent infections, immunodeficiency research, immunocompromised, immune suppression, immunosuppression, immune recovery, immune restoration, thymus, thymic function, thymic hormones, thymic involution, aging thymus, immune aging, immunosenescence, healthy immune aging, T cells, T lymphocytes, T-cell function, T-cell maturation, CD4 T cells, CD8 T cells, CD4/CD8 ratio, helper T cells, cytotoxic T cells, regulatory T cells, Tregs, dendritic cells, antigen presentation, macrophages, natural killer cells, NK cells, innate immunity, adaptive immunity, cytokines, cytokine signaling, Toll-like receptors, TLR research, immune surveillance, lymphocytes, lymphopenia, low lymphocytes, HLA-DR, monocyte HLA-DR, immune paralysis, sepsis, severe sepsis, septic shock, sepsis immune suppression, sepsis immunotherapy, sepsis mortality, TESTS trial, ETASS trial, infection, severe infection, infectious disease, viral infection research, bacterial infection research, chronic infections, opportunistic infections, respiratory infections, hepatitis, hepatitis B, HBV, chronic hepatitis B, hepatitis C, HCV research, liver infection research, liver disease research, hepatocellular carcinoma, liver cancer research, COVID-19, coronavirus research, severe COVID, Long COVID research, post-COVID immune dysfunction, SARS research, viral immunity, Epstein-Barr virus, EBV research, chronic EBV research, CMV research, cytomegalovirus, Lyme disease research, Borrelia research, tuberculosis research, TB immune research, severe acute pancreatitis, pancreatitis immune research, inflammation, inflammatory response, chronic inflammation research, immune dysregulation, hyperinflammation, autoimmune disease research, autoimmunity, autoimmune disorders, rheumatoid arthritis research, lupus research, inflammatory disease, cancer, cancer research, oncology, cancer immune system, cancer immunotherapy, tumor immune microenvironment, tumor immunity, immune surveillance cancer, cold tumors, hot tumors, tumor infiltration, T-cell infiltration, immune checkpoint inhibitors, checkpoint inhibitors, PD-1 research, PD-L1 research, CTLA-4 research, immunotherapy research, immunotherapy side effects, immune-related adverse events, chemotherapy research, chemotherapy immune suppression, radiation research, radiotherapy immune suppression, melanoma, malignant melanoma research, lung cancer, non-small cell lung cancer, NSCLC, hepatocellular carcinoma, HCC, cancer survival research, adjuvant cancer therapy research, vaccine response, vaccine immunity, vaccine response enhancer, weak vaccine response, immunocompromised vaccine response, influenza vaccine research, vaccine adjuvant research, thymalfasin clinical trials, Zadaxin clinical trials, thymosin alpha-1 clinical trials, thymosin alpha-1 sepsis, thymosin alpha-1 cancer, thymosin alpha-1 COVID, thymosin alpha-1 hepatitis, thymosin alpha-1 Lyme, thymosin alpha-1 EBV, thymosin alpha-1 autoimmune, thymosin alpha-1 inflammation, thymosin alpha-1 longevity, longevity peptide research, anti-aging research, immune longevity, thymus rejuvenation research, thymosin alpha-1 vs thymosin beta-4, thymosin alpha-1 vs TB-500, TA1 vs TB500, thymosin alpha vs beta, Tα1 vs Tβ4, thymosin alpha-1 vs LL-37, thymosin alpha-1 vs KPV, LL-37, KPV, TB-500, thymosin beta-4, peptide immunotherapy, compounded thymosin alpha-1, research thymosin alpha-1, research TA1, research thymalfasin, gray market thymosin alpha-1, FDA thymosin alpha-1, FDA thymalfasin, FDA Zadaxin, thymalfasin orphan drug, Zadaxin FDA approval, immunology peptides, research peptides.
Educational Disclaimer: This profile is provided for educational and research-information purposes only. It is not medical advice and does not provide dosing, administration, infection treatment, cancer treatment, immune therapy, compounding, or purchasing recommendations. Thymosin alpha-1 / thymalfasin has substantial international clinical research and Zadaxin is marketed in some countries, but FDA has explicitly stated that no thymosin alpha-1 product is approved in the United States. FDA also currently identifies compounded Tα1 as potentially presenting safety concerns involving immunogenicity, peptide-related impurities, API characterization, and insufficient safety information for proposed compounded uses.